"I found a treatment that's a match for me."

The first treatment specifically for metastatic non-small cell lung cancer (mNSCLC) with an abnormality in the MET gene called MET exon 14 skipping (METex14).

Important Safety Information

TABRECTA™ (capmatinib) tablets may cause serious side effects. Tell your health care provider right away if you get any of the following:

  • Lung or breathing problems. TABRECTA may cause inflammati...

See More
Approved Use

TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body or cannot be removed by surgery (metastatic), and
  • whose tumors have an abnormal mesenchymal-epithelial transitio...
See More
TESTING AND DIAGNOSIS

Biomarker testing matters

Comprehensive testing may identify METex14 status and could help inform treatment decisions.

SEE HOW
HOW TABRECTA MAY HELP

Treatment with TABRECTA

Discover proven results from the clinical trial.

SEE RESULTS